Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia)Completed
NCT04877626Phase 4Updated May 7, 2021
Sponsor: Universidad Nacional de Colombia
P. Falciparum Malaria
Colombia
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to PlaceboCompleted
NCT02957682Phase 4Updated May 7, 2021
Sponsor: Regeneron Pharmaceuticals
Hypercholesterolemia
United States, Bulgaria, Chile, Estonia, Japan +4 more
Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)Completed
NCT00228423Phase 2Updated Apr 27, 2021
Sponsor: Ottawa Heart Institute Research Corporation
Atherosclerosis
Canada
Investigating Novel Predictions of Hypoglycemia Occurrence in Real-world ModelsCompleted
NCT04219514N/AUpdated Apr 13, 2021
Sponsor: Stewart Harris
Hypoglycemia · Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1
United States
Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical RadiotherapyUnknown
NCT00653848Phase 3Updated Mar 25, 2021
Sponsor: Scandinavian Prostate Cancer Group
Prostate Cancer
Norway
Genzyme Osteopenia/Osteoporosis StudyCompleted
NCT02785744N/AUpdated Mar 23, 2021
Sponsor: NYU Langone Health
Gaucher Disease
United States
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry DiseaseCompleted
NCT02489344Phase 2Updated Mar 23, 2021
Sponsor: Genzyme, a Sanofi Company
Fabry Disease
United States, France, Poland, Russia, United Kingdom
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple SclerosisCompleted
NCT02583594Phase 1Updated Mar 10, 2021
Sponsor: Genzyme, a Sanofi Company
Progressive Multiple Sclerosis
Spain
Study of Viscosupplementation for the Treatment of Knee Pain After MenisectomyWithdrawn
NCT00971074NAUpdated Feb 25, 2021
Sponsor: Grant Jones
Arthralgia
United States
Kidney Information Network for Disease Research and EducationTerminated
NCT03321604N/AUpdated Feb 24, 2021
Sponsor: Massachusetts General Hospital
ESRD · Fabry Disease · Rare Diseases · Kidney Diseases
United States
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem CellsCompleted
NCT01753453Phase 2Updated Feb 23, 2021
Sponsor: Sanofi
Multiple Myeloma
Belgium, Estonia, Lithuania, Sweden
Seroprevalence of Pertussis Among Children and Adolescents in CroatiaUnknown
NCT04725669NAUpdated Feb 15, 2021
Sponsor: University Hospital for Infectious Diseases, Croatia
Immunogenicity, Vaccine
Croatia
Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study)Completed
NCT02824068N/AUpdated Feb 10, 2021
Sponsor: LMU Klinikum
Pompe Disease
Germany, Italy, Taiwan
A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic IrradiationTerminated
NCT00285415Phase 2Updated Feb 5, 2021
Sponsor: Carilion Clinic
Advanced Endometrial Adenocarcinoma, Stage III A, B, C
United States
Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast CancerCompleted
NCT00544765Phase 3Updated Feb 4, 2021
Sponsor: GBG Forschungs GmbH
Breast Cancer
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease CardiomyopathyUnknown
NCT04724083N/AUpdated Jan 27, 2021
Sponsor: Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Fabry
United States
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic SyndromeCompleted
NCT00017550Phase 2Updated Jan 27, 2021
Sponsor: Genzyme, a Sanofi Company
Myelodysplastic Syndromes
United States, Canada
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid LeukemiaCompleted
NCT00469014Phase 2Updated Jan 26, 2021
Sponsor: M.D. Anderson Cancer Center
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Chronic Myeloid Leukemia
United States
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTerminated
NCT02844582Phase 2Updated Jan 25, 2021
Sponsor: University of California, Davis
Hormone-Resistant Prostate Cancer · Stage IV Prostate Adenocarcinoma
United States
A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve CalcificationCompleted
NCT02481258Phase 2Updated Jan 22, 2021
Sponsor: Mayo Clinic
Aortic Valve Stenosis
United States
Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin LymphomaWithdrawn
NCT04373083Phase 2Updated Jan 15, 2021
Sponsor: Regeneron Pharmaceuticals
Hodgkin Lymphoma
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia ACompleted
NCT01181128Phase 3Updated Jan 8, 2021
Sponsor: Bioverativ Therapeutics Inc.
Severe Hemophilia A
United States, Australia, Austria, Belgium, Brazil +14 more
Consensus Method to Evaluate the Conformity of Prescription of a ChemotherapyCompleted
NCT02882178N/AUpdated Jan 8, 2021
Sponsor: Institut Bergonié
Prostate Cancer
Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate CancerTerminated
NCT03327662Phase 3Updated Jan 6, 2021
Sponsor: Institute of Cancer Research, United Kingdom
Adenocarcinoma of the Prostate
United Kingdom
Acne Vulgaris Related Microbiology and SerologyCompleted
NCT04056598N/AUpdated Jan 6, 2021
Sponsor: Sanofi
Acne Vulgaris
United States

Previous page Next page